Carvedilol Phosphate Capsule, Extended Release
Product Images NDC 42291-479

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 42291-479). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (10mg)

Carvedilol Phosphate Extended-Release Capsules 10 mg in a carton label from AvKARE. The label indicates a 30-capsule package size with once-a-day dosing. The product is prescription-only and includes storage instructions and a warning about the safety seal.*

FDA Label Image

20 (20mg)

Carvedilol Phosphate Extended-Release Capsules 20 mg in a carton labeled for 30 capsules. The label shows the dosage form as extended-release capsules, with a prescription-only designation. It is distributed by AvKARE, based in Pulaski, TN. The label includes dosage instructions and storage information, along with a barcode and NDC 42291-480-30.*

FDA Label Image

40 (40mg)

Packaging label for Carvedilol Phosphate Extended-Release Capsules, 40 mg strength. The label indicates a dose of once-a-day and a package size of 30 capsules. It includes usage instructions, storage conditions, safety warnings, and distributor information for AvKARE in Pulaski, TN.*

FDA Label Image

80 (80mg)

Label for Carvedilol Phosphate Extended-Release Capsules, 80 mg, by AvKARE. The label indicates a 30-capsule package with one capsule shown. Directions include once-a-day dosing with storage instructions and safety warnings. The labeler AvKARE is listed with address in Pulaski, TN.*

FDA Label Image

Chemical Structure (Carvedilol Phosphate Extended Release Capsules 1)

Chemical structure diagram of Carvedilol Phosphate, including annotations for phosphate and ethanol components.*

FDA Label Image

Figure 1 Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Phosphate Extended Release Capsules 2)

A line graph depicting mortality percentage over 21 months comparing Carvedilol and placebo. The x-axis represents time in months, and the y-axis shows percent mortality. The graph shows lower mortality with Carvedilol compared to placebo, with a P value of 0.0014 indicating statistical significance.*

FDA Label Image

Figure 2 Effects On Mortality For Subgroups In Copernicus (Carvedilol Phosphate Extended Release Capsules 3)

A forest plot chart displaying various patient subgroups including gender, age, race, diabetic status, ischemic status, heart rate, systolic blood pressure, and spironolactone use. Each subgroup is represented by a point estimate with corresponding confidence intervals, plotted along a horizontal axis ranging from 0.0 to 2.0, with a vertical dashed line at 1.0 indicating the reference value.*

FDA Label Image

Figure 3 Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Phosphate Extended Release Capsules 4)

A line chart showing % mortality over 24 months comparing Carvedilol and placebo. The graph indicates lower mortality with Carvedilol than with placebo, with data points labeled for each group and a statistical significance notation (P = 0.03). The x-axis represents months, and the y-axis represents percent mortality.*

FDA Label Image

Figure 4 Effects On Mortality For Subgroups In Capricorn (Carvedilol Phosphate Extended Release Capsules 5)

A forest plot chart depicting hazard ratios for various subgroups, including age, sex, timing of randomization post-myocardial infarction, prior use of beta-blockers, Killip classification, thrombolytic therapy, percutaneous coronary intervention, congestive heart failure status, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure categories. Each subgroup is represented with a point estimate and confidence interval along the hazard ratio scale ranging from 0.4 to 1.3.*

FDA Label Image

Figure 5. Changes From Baseline In Systolic Blood Pressure And Diastolic Blood Pressure Measured By 24-hour Abpm (Carvedilol Phosphate Extended Release Capsules 6)

Line charts showing changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of carvedilol phosphate extended-release capsules at 20 mg, 40 mg, and 80 mg dosages. The x-axis represents time after dose in hours, and the y-axis represents change in mmHg for SBP and DBP. Lines are smoothed using locally weighted regression smoothing methodology.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.